Has Suchet Patel, MD received payments from drug or device companies?

Yes. Drug and device makers reported $23,259,373 in general payments to Suchet Patel, MD across 2,228 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Suchet Patel, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Suchet Patel, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Suchet Patel, MD

Family Medicine · Endwell, NYNPI 1942229018

Payments from drug & device makers

$23,259,373in general payments, 2019–2025

Across 2,228 payments — averaging $10,440 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$9.3M
Modernatx, Inc.$6.6M
Valneva Austria GmbH$1.6M
Seqirus USA Inc$1.1M
Merck$1.1M
Janssen Research & Development, LLC$988K
plus $2.6M from 40 others

$229,119in research payments, 2019–2025

Across 9 payments — averaging $25,458 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Valneva Austria GmbH$229K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	428	$9,280,065
Modernatx, Inc.	329	$6,616,402
Valneva Austria GmbH	50	$1,582,309
Seqirus USA Inc	587	$1,103,164
Merck	60	$1,098,158
Janssen Research & Development, LLC	80	$988,071
Boehringer Ingelheim	47	$545,908
Johnson & Johnson	36	$478,886
Bavarian Nordic A/s	64	$472,509
Amgen	8	$214,006
Sanofi Pasteur Inc.	21	$195,509
Takeda Pharmaceuticals U.S.A., Inc.	97	$194,501
Eli Lilly	6	$104,391
Novartis	19	$90,598
Novavax Inc	30	$89,390
Regeneron	27	$67,373
Boehringer Ingelheim International GmbH	164	$62,354
Astrazeneca UK Limited	2	$26,463
AstraZeneca	6	$21,307
GSK	25	$16,726
Adaptive Biotechnologies Corporation	1	$7,834
Eisai Inc.	1	$850
AbbVie(2 entities)	30	$635
Novo Nordisk	41	$615
Lilly USA, LLC	18	$300
Axsome Therapeutics, Inc.	10	$196
Bard Peripheral Vascular, Inc.	2	$191
Abbott	8	$132
Phathom Pharmaceuticals, Inc.	7	$122
Corcept Therapeutics	4	$61
Edwards Lifesciences	1	$46
Corium, LLC	4	$46
Irhythm Technologies, Inc.	1	$38
Astellas Pharma US Inc	1	$25
Nevro Corp.	1	$24
Verona Pharma, Inc.	1	$22
Neurocrine Biosciences, Inc.	1	$19
Otsuka America Pharmaceutical, Inc.	1	$17
Sumitomo Pharma America, Inc.	1	$17
Biohaven Pharmaceutical Holding Company Ltd.	1	$15
Gilead	1	$14
Si-bone, Inc.	2	$14
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	1	$14
Bayer	1	$13
Teva Pharmaceuticals USA, Inc.	1	$12
Neuronetics, Inc.	1	$10

How this compares

$23,259,373 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York →

Medicare billing

Part B allowed, 2024

$73,771

Medicare patients

157

Services billed

2,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Endwell

Michael FedericoEndwell$1.4M
Kimberly DesantisEndwell$1.1M
Eric LorraineEndwell$740K
Bruce BowlingEndwell$287K
Duncan Sze-TuEndwell$227K
Rekha PatelEndwell$161K
Matthew DavisRochester$76.6M
Frank EderBinghamton$46.2M
James WildGowanda$2.2M
Donald BrautigamWestfield$1.3M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →